Sarepta Therapeutics crisis is huge blow to Duchenne families, company
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Patient dies in Sarepta gene therapy trial, adding to safety concerns
A 51-year-old man died last month after receiving an experimental gene therapy developed by Sarepta Therapeutics for an…
Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting move
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA rejects Capricor’s Duchenne cell therapy
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Kennedy abruptly cancels U.S. Preventive Services Task Force meeting
WASHINGTON — Health secretary Robert F. Kennedy Jr. has abruptly canceled a meeting of a key expert panel that…